Apr, 2010

U.S.A.
News / Therapeutic Area News
FDA Approves Tarceva as a Maintenance Therapy for Advanced Non-Small Cell Lung Cancer
MELVILLE, N.Y., Apr 16, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Food and Drug Administration (FDA) approved the daily pill Tarceva(R)...
Read More
U.S.A.
News / Therapeutic Area News
Number of Americans Willing to Donate Organs Rises, But Still Not Keeping Pace with Need
RICHMOND, Va. (April 5, 2010) – According to a new survey by Donate Life America, 43 percent of people are undecided, reluctant or do not wish to have their organs and tissue donated after their...
Read More

Mar, 2010

U.S.A.
News / Therapeutic Area News
OSI Pharmaceuticals Announces That Tarceva(R) Received a Positive Opinion from Health Authorities in the European Union for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
MELVILLE, N.Y., Mar 19, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its international partner for Tarceva(R) (erlotinib), Roche, informed OSI that the...
Read More

Jan, 2010

U.S.A.
News / Therapeutic Area News
FDA Extends Review Period for Tarceva Application for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
MELVILLE, N.Y. & SOUTH SAN FRANCISCO, Calif., Jan 15, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG;...
Read More
U.S.A.
News / Therapeutic Area News
SUMAVEL™ DosePro™ Available in the United States to Treat Acute Migraine and Cluster Headaches
SAN DIEGO, Calif. and DEERFIELD, Ill., January 13, 2010 — Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company, and Astellas Pharma US, Inc. (“Astellas”) announced today...
Read More